FDA approves Servier’s Voranigo for grade 2 IDH-mutated glioma

Voranigo is the first targeted therapy in nearly 25 years approved by the FDA for grade 2 astrocytomas or oligodendrogliomas with susceptible IDH1 or IDH2 mutations following surgery.